#Canada #financial results #Laval #Bausch Health #Q2 2026

Bausch Health Companies Inc. Reports Strong Second Quarter 2026 Results

On July 29, 2026, Bausch Health Companies Inc. detailed its impressive financial outcomes for the second quarter of 2026, showcasing substantial revenue growth and an optimistic outlook for the remainder of the year. This quarter marks the thirteenth consecutive period of year-over-year revenue growth, highlighting the resilience and adaptability of the company's business strategies.

Key Financial Highlights

• - Consolidated Revenues: Bausch Health reported consolidated revenues of $2.85 billion, reflecting a 13% increase compared to the same quarter in 2025. Excluding foreign exchange effects and acquisitions, organic revenue rose by 11%.
• - Net Income: The net income attributable to Bausch Health reached $258 million, compared to $148 million in the second quarter of the prior year, indicating strong financial performance.
• - Earnings per Share (EPS): The diluted EPS increased to $0.68, up from $0.40 in the previous year, while adjusted earnings per share surged to $1.26 from $0.90.
• - Adjusted EBITDA: The adjusted EBITDA attributable to Bausch Health was reported at $1,075 million, up 28% from the previous year, showcasing enhanced operational efficiency.
• - Crucial Business Segments: The Salix segment saw a remarkable 21% revenue growth, driven primarily by the success of its flagship product, Xifaxan®. The Solta Medical segment also performed well, with revenues up 38%.

Revenue Performance by Segment

Bausch Health’s revenue growth was robust across various segments, reflecting strategic execution and market demand:

• - Bausch Health (excluding Bausch + Lomb): Revenue hit $1.46 billion, a 16% increase.
• - Salix: Achieved $758 million in revenues with a 21% increase.
• - International Segment: Reported revenues of $305 million, marking a growth of 10%.
• - Solta Medical: Generated $176 million, indicating a 38% growth from the prior year.
• - Diversified Segment: Maintained steady revenue of $219 million.
• - Bausch + Lomb: Revenue increased by 9%, totaling $1.39 billion.

Increased Guidance for 2026

Due to the favorable quarter results, Bausch Health raised its full-year guidance for both revenue and adjusted EBITDA. The company forecasted consolidated revenues between $10.79 billion and $11.04 billion, a revenue growth of 4% to 6% compared to 2025. Adjusted EBITDA expectations were also lifted to around $4.050 billion to $4.175 billion for the full year.

CEO Thomas J. Appio remarked, “The second quarter marks a significant achievement for us, reflecting the strength of our portfolio and the dedication of our teams globally. We’ve seen substantial revenue and earnings growth across multiple segments, which enhances our financial stability and allows for continued investments in our business and pipeline.”

Financial Flexibility and Strategic Priorities

Bausch Health noted a significant cash flow generation of $671 million during the quarter, up 132% from previous year levels. This robust cash flow places the company in a position to further invest in its strategic initiatives, including product development and market expansion.

The company aims to optimize shareholder value by exploring all options for enhancing its assets, particularly within its Bausch Health and Bausch + Lomb segments. As Bausch Health embarks on the second half of 2026, the focus remains on leveraging this financial momentum while navigating the evolving market landscape effectively.

The expectations for the upcoming quarters remain positive, with an emphasis on maintaining growth trajectories across all operational segments, ensuring that Bausch Health continues to deliver value to its stakeholders.